Class summary at a glance.

Every drug in the Anticonvulsant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $830.3Mcombined across class
Total Rx claims: 13.9M3.1M unique beneficiaries
Generic mfrs (active): 103across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Levetiracetam

Brand: Keppra · 7.4M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 2000-04-24

52 generic mfrs 102 plans require PA

Low NADAC$0.030

→

Avg plan cost$0.917

Part D spend $384.3M 30× spread, current vs floor

Class share

46%

of class CY24 spend

View profile →

Lacosamide

Brand: MOTPOLY XR · 1.4M Part D claims (CY24) · 243K beneficiaries · First FDA approval: 2009-05-26

28 generic mfrs 12 plans require PA

Low NADAC$0.095

→

Avg plan cost$2.54

Part D spend $252.2M 27× spread, current vs floor

Class share

30%

of class CY24 spend

View profile →

Topiramate

Brand: Eprontia · 5.1M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 1997-01-01

23 generic mfrs 373 plans require PA Discontinued

Low NADAC$0.026

→

Avg plan cost$4.58

Part D spend $193.8M 176× spread, current vs floor

Class share

23%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.